In vitro–in vivo correlation and bioavailability studies of captopril from novel controlled release donut shaped tablet

Mandal, Asim Sattwa; Chatterjee, Sugata; Kundu, Subhasis; Biswas, Nirmalendu; Guha, Arun K.; Paul, Sreyashi; Kuotsu, Ketousetuo

doi:10.1016/j.ijpharm.2011.09.012

Cited by 5 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concentrations of sirolimus in dissolution medium were determined every two days by enzyme amplification immunoassay for a consecutive period of 42 days [13]. Drug release, cumulative release and residual amount of drugs in DES were determined.…”

Section: Evaluation Of Pharmacokinetics Of Des In Vitromentioning

confidence: 99%

<i>In vitro</i> pharmacokinetics of sirolimus-coated stent for tracheal stenosis

Wang¹,

Chen²,

Lin³

et al. 2017

Trop. J. Pharm Res

View full text Add to dashboard Cite

Section: Evaluation Of Pharmacokinetics Of Des In Vitromentioning

confidence: 99%

<i>In vitro</i> pharmacokinetics of sirolimus-coated stent for tracheal stenosis

Wang¹,

Chen²,

Lin³

et al. 2017

Trop. J. Pharm Res

View full text Add to dashboard Cite

“…The simplicity of the method was the trade‐off for the sensitivity as shown by the limit of quantitation (LOQ) and LOD in Table . A more sensitive method was developed by Mandal et al [] where the absorbance was measured at 204 nm using a mobile phase acetonitrile/phosphate buffer pH 3.2 (60:40, v/v). However, there was significant peak overlap from matrix compounds for both the internal standard ramipril peak as well as the CAP peak, potentially compromising the accuracy of peak integration.…”

Section: Liquid Chromatographymentioning

confidence: 99%

Separation methods for captopril in pharmaceuticals and biological fluids

Mansour¹,

Danielson²

2012

J of Separation Science

View full text Add to dashboard Cite

Captopril (CAP) is an orally active angiotensin‐converting enzyme (ACE) inhibitor and has been widely used for management of hypertension and congestive heart failure. CAP lacks an aromatic chromophore required for facile direct UV detection and also has two chiral centers. These factors can render the determination of CAP in complex matrices challenging. This review covers more than 20 years of analytical research on this drug, focusing mainly on pharmaceutical and biological applications. The primary separation techniques discussed are gas chromatography, liquid chromatography, and capillary electrophoresis. The structures of the CAP derivatizing agents as well as a table summarizing various HPLC methods are provided. A discussion of key recent chromatographic and electrophoretic methods for other ACE inhibitors is also present.

show abstract

“…Some researchers have found that a variety of the side effects caused by captopril occur because of its sulfhydryl group, and therefore replacing it with an ester group resulted in the production of enalapril 5,6 . In addition, sustained‐release technology has been investigated to prolong the efficacy and duration of captopril 7,8 . Kok et al 9 .…”

Section: Introductionmentioning

confidence: 99%

Antihypertensive effect of rapeseed peptides and their potential in improving the effectiveness of captopril

et al. 2020

View full text Add to dashboard Cite

BACKGROUND The main objective of this study was to evaluate the safety and antihypertensive activity of rapeseed peptides and to investigate their potential synergy with captopril. RESULTS The peptides were nontoxic with the maximum tolerated dose exceeding 25 g kg−1 BW d−1 for mice and they had angiotensin converting enzyme (ACE) inhibitory activity with IC50 value of 1.27 mg mL−1. Rapeseed peptides did not have a synergistic effect with captopril on inhibiting ACE activity in simulated digestion tests in vitro. But in vivo they could synergistically augment the amplitude range of lowering blood pressure with captopril by approximately 9% and prolong the antihypertensive effect duration time by over 20% in antihypertension tests of spontaneously hypertensive rats. In addition, the inhibiting effect of rapeseed peptides on ACE activity was noticeable in some rat organs in vivo. Nevertheless, when compared to captopril group, the potential synergy of rapeseed peptides with captopril did not cause a further decrease in ACE activity in the organs but their synergy further improved levels of NO (12.7%) and endothelial nitric oxide synthase (74.1%) in rat serum. Further studies of some peptides identified from rapeseed peptides showed that some of the rapeseed peptides (Cys‐Leu, Val‐Ala‐Pro) could markedly increase contents of NO and endothelial nitric oxide synthase. CONCLUSIONS Rapeseed peptides have antihypertensive activity and they showed potential synergy with captopril in antihypertensive performance in vivo. The synergy was not from ACE inhibition but from other pathways, like improvement in endogenous vasodilator contents. © 2020 Society of Chemical Industry

show abstract

In vitro–in vivo correlation and bioavailability studies of captopril from novel controlled release donut shaped tablet

Cited by 5 publications

References 18 publications

<i>In vitro</i> pharmacokinetics of sirolimus-coated stent for tracheal stenosis

<i>In vitro</i> pharmacokinetics of sirolimus-coated stent for tracheal stenosis

Separation methods for captopril in pharmaceuticals and biological fluids

Antihypertensive effect of rapeseed peptides and their potential in improving the effectiveness of captopril

Contact Info

Product

Resources

About